These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33240282)

  • 1. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
    Jørgensen NG; Klausen U; Grauslund JH; Helleberg C; Aagaard TG; Do TH; Ahmad SM; Olsen LR; Klausen TW; Breinholt MF; Hansen M; Martinenaite E; Met Ö; Svane IM; Knudsen LM; Andersen MH
    Front Immunol; 2020; 11():595035. PubMed ID: 33240282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
    Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
    Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.
    Jørgensen NG; Kaae J; Grauslund JH; Met Ö; Nielsen SL; Pedersen AW; Svane IM; Ehrnrooth E; Andersen MH; Zachariae C; Skov L
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Kjeldsen JW; Lorentzen CL; Martinenaite E; Ellebaek E; Donia M; Holmstroem RB; Klausen TW; Madsen CO; Ahmed SM; Weis-Banke SE; Holmström MO; Hendel HW; Ehrnrooth E; Zocca MB; Pedersen AW; Andersen MH; Svane IM
    Nat Med; 2021 Dec; 27(12):2212-2223. PubMed ID: 34887574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
    Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
    Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM
    Front Immunol; 2022; 13():1023023. PubMed ID: 36330525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-immunizing with PD-L1 induces CD8
    Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
    Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
    Kuball J; de Boer K; Wagner E; Wattad M; Antunes E; Weeratna RD; Vicari AP; Lotz C; van Dorp S; Hol S; Greenberg PD; Heit W; Davis HL; Theobald M
    Cancer Immunol Immunother; 2011 Feb; 60(2):161-71. PubMed ID: 20963411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
    Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
    Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
    Graham BS; McElrath MJ; Keefer MC; Rybczyk K; Berger D; Weinhold KJ; Ottinger J; Ferarri G; Montefiori DC; Stablein D; Smith C; Ginsberg R; Eldridge J; Duerr A; Fast P; Haynes BF;
    PLoS One; 2010 Aug; 5(8):e11995. PubMed ID: 20706632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
    Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
    J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Bloch O; Lim M; Sughrue ME; Komotar RJ; Abrahams JM; O'Rourke DM; D'Ambrosio A; Bruce JN; Parsa AT
    Clin Cancer Res; 2017 Jul; 23(14):3575-3584. PubMed ID: 28193626
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
    Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
    JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
    Clancy-Thompson E; King LK; Nunnley LD; Mullins IM; Slingluff CL; Mullins DW
    Cancer Immunol Res; 2013 Nov; 1(5):332-9. PubMed ID: 24377099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.